Study S001555

Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05486065
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 245
Start: 2022-08-08
Primary completion: 2023-10-12
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1271-9209; EUDRACT_NUMBER:2022-000882-41

Registered primary outcomes

Change in Glycated Haemoglobin (HbA1c) [Baseline (week 0) and End of treatment (week 40)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0045712	High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight/obesity: a randomized, placebo-controlled, phase 2 trial Vanita R. Aroda	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05486065